In Metastatic Prostate Cancer, Radiographic PFS Associated with Survival
the Cancer Therapy Advisor take:
According to a new study published by the Journal of Clinical Oncology, researchers have found that radiographic progression-free survival (rPFS) was highly consistent and associated with overall survival in a randomized trial of abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Because progression-free survival in mCRPC studies has been inconsistently defined and poorly associated with overall survival, researchers sought to study a reproducible quantitative definition of rPFS to test for an association with overall survival.
Researchers defined rPFS as "≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 12 weeks after random assignment, and/or progression in nodes or viscera on cross-sectional imaging, or death."
Results showed hazard ratios of 0.49 (95% CI: 0.41 - 0.60; P <0.001) and 0.53 (95% CI: 0.45 - 0.62; P < 0.001). The Spearman's correlation coefficient between rPFS and overall survival was 0.72.
The findings suggest that rPFS should be further developed as an intermediate endpoint in trials studying patients with mCRPC.
Radiographic progression-free survival was highly associated with overall survival in metastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol